---
document_datetime: 2024-09-18 14:44:38
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/peyona-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: peyona-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3991672
conversion_datetime: 2025-12-28 11:20:16.954701
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Peyona

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IB/0032              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 27/03/2024                          |                                             | SmPC and PL                      |                                   |
| PSUSA/482/2 02307    | Periodic Safety Update EU Single assessment - caffeine (apnea)                                 | 08/02/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0031     | B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product                                                                                                                                                                                                                                                        | 26/01/2024   | n/a   |              |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------|
| IB/0028     | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/12/2023   | n/a   |              |
| IA/0027/G   | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a | 14/04/2023   | n/a   | Member State |
| IAIN/0026/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                               | 01/09/2022   | n/a   | site         |

<div style=\"page-break-after: always\"></div>

| N/0025              | Minor change in labelling or package leaflet not                                                                                              | 14/12/2021   | 19/05/2022   | PL                         |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------|-----------------------------------|
| IB/0024             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 10/08/2021   | n/a          |                            |                                   |
| PSUSA/482/2 02007   | Periodic Safety Update EU Single assessment - caffeine (apnea)                                                                                | 11/02/2021   | n/a          |                            | PRAC Recommendation - maintenance |
| IB/0023             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 27/10/2020   | 19/05/2022   | SmPC, Annex II and PL      |                                   |
| N/0021              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                              | 20/11/2018   | 19/05/2022   | PL                         |                                   |
| PSUSA/10615 /201707 | Periodic Safety Update EU Single assessment - caffeine (apnea, centrally authorised product only)                                             | 08/03/2018   | n/a          |                            | PRAC Recommendation - maintenance |
| IAIN/0019           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                    | 21/09/2017   | 19/04/2018   | Annex II and PL            |                                   |
| IB/0018             | B.II.e.5.z - Change in pack size of the finished product - Other variation                                                                    | 27/07/2017   | n/a          |                            |                                   |
| IB/0017             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 19/04/2017   | 19/04/2018   | Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0016           | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                             | 23/11/2016   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013           | Update of the statement regarding hepatic and renal impairment patients in sections 4.2 and 4.4, and section 4.8 of the SmPC to reflect the results of an European Non-Interventional Post-Authorisation Study to assess drug utilisation and safety of caffeine citrate in the treatment of premature infants affected by apnoea. This study addresses a post- authorisation measure in the RMP. Section 4 of the package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/02/2015   | 24/02/2016 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/482/2 01407 | Periodic Safety Update EU Single assessment - caffeine (apnea)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 04/12/2014   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                              |
| R/0011            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/12/2013   | 03/03/2014 | SmPC, Annex II, Labelling and PL | Base on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Peyona continues to be favourable. The CHMP was of the opinion that the renewal could be granted with unlimited validity. |
| PSUV/0012         | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/01/2014   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| N/0010      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                              | 13/08/2013   | 03/03/2014   | PL   |     |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|-----|
| IAIN/0009   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                | 13/02/2013   | n/a          |      |     |
| IAIN/0008   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same                                                                                                                                                                                                                                                                                       | 13/04/2012   | n/a          |      | MAH |
| IAIN/0007/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 24/02/2012   | n/a          |      |     |
| N/0006      | Update of the list of local representatives contact details in the package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                          | 11/01/2012   | 31/05/2012   | PL   |     |

<div style=\"page-break-after: always\"></div>

| IA/0005   | - Administrative change - Change in the name address of a manufacturer responsible for release                                                                                                                                                                                                                                                                                                      | 19/10/2011   | 31/05/2012   | Annex II and PL                  | A.5.a and/or batch    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------|
| IA/0004/G | This was an application for a group of variations. C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 25/11/2010   | n/a          | Annex II                         | the pharmacovigilance |
| IA/0003   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                                                                                                                                                                                     | 24/11/2010   | n/a          | SmPC, Annex II, Labelling and PL |                       |
| II/0002   | Addition of a new presentation of 1 ml ampoule 20 mg/ml. B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, and biological/immunological multidose parenteral medicinal products                                                                                    | 22/04/2010   | 04/06/2010   | SmPC, Labelling and PL           |                       |
| IA/0001   | To update the European Pharmacopeia Certificate of Suitability (R1-CEP 1998-022-Rev 02)                                                                                                                                                                                                                                                                                                             | 16/02/2010   | n/a          |                                  |                       |

<div style=\"page-break-after: always\"></div>

| B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|